Slate begins first-in-human test of dual PACAP/VIP antibody for migraine

Slate Medicines said Thursday that it dosed the first participant in a Phase 1 study of SLTE-1009, an investigational monoclonal antibody designed to neutralize two neuropeptides implicated in migraine: pituitary adenylate cyclase-activating polypeptide, or PACAP, and vasoactive intestinal peptide, or VIP.

The August 27 announcement moves the candidate into human testing, but it does not provide evidence that SLTE-1009 prevents migraine. The Australian study enrolls healthy adults and is designed principally to characterize safety, tolerability and how the antibody moves through the body. Slate expects initial safety and pharmacokinetic findings in mid-2027.

What the Phase 1 study will measure

The prospectively registered trial has a target enrollment of 72 healthy volunteers ages 18 to 55. Its scientific title describes a randomized, double-blind, placebo-controlled study divided into single- and multiple-ascending-dose portions.

In the single-dose portion, groups of eight participants are assigned in a 3-to-1 ratio to SLTE-1009 or saline placebo. Five planned cohorts test intravenous doses ranging from 50 to 1,000 milligrams, with sentinel participants dosed before the remainder of each cohort. The multiple-dose portion uses the same allocation ratio across three planned cohorts. Participants receive subcutaneous injections on days 1, 15 and 29, with proposed dose levels of 150, 300 and 600 milligrams subject to findings from the single-dose stage.

Primary assessments include adverse events, vital signs, electrocardiograms, laboratory measurements and physical examinations. Follow-up extends through day 169 for the single-dose portion and day 197 for the multiple-dose portion. Secondary endpoints include drug concentrations over time and the development of antibodies against SLTE-1009.

These endpoints may establish whether further development is reasonable and help select later doses. They cannot show whether the candidate reduces migraine frequency because the participants are healthy and clinical efficacy is not an endpoint.

Why PACAP is attracting drug developers

PACAP is a signaling peptide involved in vascular and nervous-system biology. Human evidence supports it as a plausible migraine target, although that evidence concerns other molecules—not SLTE-1009.

A published Phase 2 trial enrolled 237 adults with episodic or chronic migraine for whom two to four preventive treatments had failed. A single intravenous infusion of 750 milligrams of the PACAP-neutralizing antibody then known as Lu AG09222 reduced monthly migraine days by an adjusted two days more than placebo over weeks one through four. The confidence interval ranged from 0.3 to 3.8 fewer days, and the lower 100-milligram dose did not demonstrate the same clear advantage.

That trial supplies clinical validation for inhibiting PACAP, but it cannot be treated as efficacy evidence for SLTE-1009. Slate’s candidate is a distinct antibody engineered to bind both PACAP and VIP. The company argues that dual neutralization and half-life extension could support broader pathway blockade and infrequent subcutaneous administration. Both propositions remain hypotheses until tested in comparative clinical studies.

A registry discrepancy needs watching

The public Australian registry had not fully caught up with Slate’s announcement as of August 28. It still labeled the study “not yet recruiting,” listed August 28 as the anticipated first-enrollment date and displayed an ethics application as submitted but not yet approved. Slate’s announcement said dosing occurred August 27, while an earlier SEC filing said the company had received clearance to begin the Australian study.

Registry updates can lag trial activity, but the mismatch means the first-dose chronology currently rests on the sponsor’s statement. It should be checked again when the record is updated.

For now, SLTE-1009 is best understood as an early safety experiment built around a clinically interesting neuropeptide pathway. No results have been reported, no migraine patients have been studied with this candidate, and neither preventive benefit nor a quarterly dosing schedule has been established.